Zykadia (ceritinib) / Novartis 
Welcome,         Profile    Billing    Logout  
 20 Diseases   18 Trials   18 Trials   1690 News 


«12345678910111213...1920»
  • ||||||||||  Zykadia (ceritinib) / Novartis
    Journal:  Environment-Sensitive Fluorescent Probe Enables Assessment of Anaplastic Lymphoma Kinase Activity in Nonsmall Cell Lung Cancer. (Pubmed Central) -  Feb 28, 2024   
    HX16 is a multifunctional chemical tool based on the pharmacophore of ALK-TKI (ceritinib) and can specifically target the kinase domain of ALK with a high sensitivity...Importantly, HX16 was also applied to visualize ALK activity in a tumor biopsy from a NSCLC patient with ALK-echinoderm microtubule-associated protein-like-4 fusion gene for prediction of ALK-TKI sensitivity. These results demonstrate that strategically designed ALK-TKI-based probe allows the assessment of ALK activity in tumor tissues and hold promise as a useful diagnostic tool in predicting ALK-TKI therapy response.
  • ||||||||||  Zykadia (ceritinib) / Novartis
    Journal:  Therapeutic Implications of Ceritinib in Cholangiocarcinoma beyond ALK Expression and Mutation. (Pubmed Central) -  Feb 24, 2024   
    Standard chemotherapy involves gemcitabine-based therapies combined with cisplatin, oxaliplatin, capecitabine, or 5-FU with a dismal prognosis for most patients...Additionally, ceritinib and cisplatin synergistically reduced CCA cell viability. Our data show ceritinib as an effective treatment of CCA, which could be potentially explored in the other cancer types without ALK mutations.
  • ||||||||||  Journal, Metastases:  China expert recommendations on anaplastic lymphoma kinase-tyrosine kinase inhibitors treatment for advanced non-small cell lung cancer (2024 edition) (Pubmed Central) -  Feb 10, 2024   
    To standardize the application of ALK-TKI, the Chinese Association for Clinical Oncologists and the Medical Oncology Branch of China International Exchange and Promotive Association for Medical and Health Care has organized experts to compile the " China expert recommendations on anaplastic lymphoma kinase-tyrosine kinase inhibitors treatment for advanced non-small cell lung cancer (2024 edition)". This treatment expert recommendation provides recommendations in four aspects, encompassing ALK fusion testing, ALK-TKI targeted therapy, ALK-TKI adverse events management, and patient post-treatment follow-up, thus serving as a valuable reference for the standardized treatment of Chinese advanced ALK fusion-positive NSCLC.
  • ||||||||||  Zykadia (ceritinib) / Novartis
    Journal:  A small-molecule degrader selectively inhibits the growth of ALK-rearranged lung cancer with ceritinib resistance. (Pubmed Central) -  Feb 8, 2024   
    This treatment expert recommendation provides recommendations in four aspects, encompassing ALK fusion testing, ALK-TKI targeted therapy, ALK-TKI adverse events management, and patient post-treatment follow-up, thus serving as a valuable reference for the standardized treatment of Chinese advanced ALK fusion-positive NSCLC. Furthermore, dEALK1 also exerts a potent antitumor activity against EML4-ALK-positive xenograft tumors without or with harboring ceritinib-resistant EML4-ALK mutations in
  • ||||||||||  Lorbrena (lorlatinib) / Pfizer
    Review, Journal:  From Development to Place in Therapy of Lorlatinib for the Treatment of ALK and ROS1 Rearranged Non-Small Cell Lung Cancer (NSCLC). (Pubmed Central) -  Jan 11, 2024   
    So, when prescribing lorlatinib, clinicians must face two diametrically opposed characteristics: a great therapeutic potential without the intrinsic limitations of its precursor TKIs, a cytotoxic activity threatened by suboptimal tolerability, and the unavoidable onset of resistance mechanisms we cannot properly manage yet. In this paper, we give a critical point of view on the stepwise introduction of this promising drug into clinical practice, starting from its innovative molecular and biochemical properties to intriguing future developments, without forgetting its weaknesses.
  • ||||||||||  batoprotafib (TNO155) / Novartis
    Journal:  SHP2 inhibition with TNO155 increases efficacy and overcomes resistance of ALK inhibitors in neuroblastoma. (Pubmed Central) -  Jan 2, 2024   
    Finally, we show that lorlatinib-resistant ALK-F1174L neuroblastoma cells harbor additional RAS-MAPK pathway alterations and can be re-sensitized to lorlatinib when combined with TNO155 in vitro and in vivo. Our results report the first evaluation of TNO155 in neuroblastoma and suggest that combinatorial inhibition of ALK and SHP2 could be a novel approach to treating ALK-driven neuroblastoma, potentially including the increasingly common tumors that have developed resistance to ALK-TKIs.
  • ||||||||||  Trial completion date, Trial primary completion date, IO biomarker, Metastases:  PIKACHU: Treatment Strategies and Survival Outcome for Non-small Cell Lung Cancer With Oncogenic Mutation (clinicaltrials.gov) -  Dec 26, 2023   
    P=N/A,  N=100, Recruiting, 
    Our results report the first evaluation of TNO155 in neuroblastoma and suggest that combinatorial inhibition of ALK and SHP2 could be a novel approach to treating ALK-driven neuroblastoma, potentially including the increasingly common tumors that have developed resistance to ALK-TKIs. Trial completion date: Dec 2023 --> Dec 2025 | Trial primary completion date: Dec 2022 --> Dec 2024
  • ||||||||||  Zykadia (ceritinib) / Novartis
    Journal:  Safety and Effectiveness of Zykadia (Pubmed Central) -  Dec 5, 2023   
    The median progression- free survival was approximately 4 months. The safety and efficacy were similar to those of previous reports, and this study confirmed that there are no problems requiring additional precautions in clinical use of Zykadia
  • ||||||||||  Zykadia (ceritinib) / Novartis, Mekinist (trametinib) / Novartis, BeiGene
    Trial primary completion date:  Study of Trametinib + Ceritinib in Patients With Unresectable Melanoma (clinicaltrials.gov) -  Nov 15, 2023   
    P1,  N=27, Active, not recruiting, 
    The data are relevant for understanding putative toxic and cytotoxic side effects of these drugs such as the triggering of cell lysis or apoptosis. Trial primary completion date: Oct 2023 --> Jan 2023
  • ||||||||||  Review, Journal:  Update of Diagnosis and Targeted Therapy for ALK Inflammation Myofibroblastic Tumor. (Pubmed Central) -  Nov 8, 2023   
    After the approval of crizotinib, other ALK-TKIs, such as ceritinib, alectinib, brigatinib, and lorlatinib, have proven their efficacy on ALK IMT with sporadic case reports. The sequential treatments of targeted therapies in may provide the insight into the choice of ALK-TKIs in different lines of treatment for unresectable ALK IMT.
  • ||||||||||  Zykadia (ceritinib) / Novartis, Kisqali (ribociclib) / Novartis, Stivarga (regorafenib) / Bayer
    Real-world adverse events of targeted therapy reported by pharmacist in oncology clinic (Exhibition area) -  Oct 6, 2023 - Abstract #ESMOAsia2023ESMO_Asia_947;    
    Rarely severe AEs were reported. Health care providers will need to educate and monitor cancer patients to prevent and monuments AEs during targeted therapy treatment.
  • ||||||||||  Review, Journal, PD(L)-1 Biomarker, Metastases:  Treatment of advanced ALK-rearranged NSCLC following second-generation ALK-TKI failure. (Pubmed Central) -  Sep 29, 2023   
    In cases of ALK-dependent resistance mutations, lorlatinib could be the first choice as it exhibits the broadest coverage of mutations that lead to resistance against second-generation ALK - TKIs, such as G1202R, and L1196M. In cases of no resistance mutations, atezolizumab, bevacizumab and platinum-based chemotherapy could be the alternative treatment option.
  • ||||||||||  Zolinza (vorinostat) / Merck (MSD), Zykadia (ceritinib) / Novartis, NN1213 / Novo Nordisk
    Trial completion date, Trial primary completion date, Metastases:  PEDS-PLAN: Pediatric Precision Laboratory Advanced Neuroblastoma Therapy (clinicaltrials.gov) -  Sep 28, 2023   
    P2,  N=500, Recruiting, 
    In cases of no resistance mutations, atezolizumab, bevacizumab and platinum-based chemotherapy could be the alternative treatment option. Trial completion date: Sep 2032 --> Sep 2035 | Trial primary completion date: Sep 2027 --> Sep 2030
  • ||||||||||  Xalkori (crizotinib) / Pfizer, Zykadia (ceritinib) / Novartis, Fotivda (tivozanib) / Kyowa Kirin, Jazz, LG Chem
    Journal:  Comparative docking analysis of tyrosine kinase inhibitors with HER2 and HER4 receptors. (Pubmed Central) -  Sep 1, 2023   
    Lapatinib is identified as a potential inhibitor for both the RTKs. Our study thus suggests the probable direction that could be further explored in inhibiting EGFR protein harboring breast cancer.
  • ||||||||||  Safety and Efficacy of Stereotactic Radiosurgery with Concurrent Targeted Systemic Therapy for Brain Metastases (Hall B2; In Person Only; Screen: 11) -  Aug 22, 2023 - Abstract #ASTRO2023ASTRO_663;    
    Although heterogeneous, patients treated with SRS/SRT and ongoing CNS-active targeted systemic therapies have on average >6 month intracranial PFS and little evidence of significant toxicity. We observed <6% G2+ radiation necrosis for this cohort, and no particular class of agent was associated with a significantly higher rate of G2+ radiation necrosis.
  • ||||||||||  Zykadia (ceritinib) / Novartis
    Journal:  N76-1, a novel CDK7 inhibitor, exhibits potent anti-cancer effects in triple negative breast cancer. (Pubmed Central) -  Aug 14, 2023   
    In this study, we obtained an inhibitor of CDK7, N76-1, by attaching the side chain of the covalent CDK7 inhibitor THZ1 to the core of the anaplastic lymphoma kinase inhibitor ceritinib...Moreover, N76-1 markedly inhibited the growth of TNBC xenografts and phosphorylation of RNAPII in tumor tissues. In summary, N76-1 exerts potent anticancer effects in TNBC by inhibiting CDK7 and provides a new strategy and research basis for the development of new drugs for TNBC.
  • ||||||||||  Xalkori (crizotinib) / Pfizer, Zykadia (ceritinib) / Novartis
    Journal:  Activity of ceritinib in crizotinib-resistant ROS1-rearranged non-small-cell lung cancer patients. (Pubmed Central) -  Jul 25, 2023   
    In addition, of the 6 patients with brain metastases, an intracranial disease control rate of 66.7% (95% CI:12.5% to 120.9%) was obtained. The research results reveal that ceritinib can be a treatment option for ROS1-rearranged NSCLC patients after the development of crizotinib resistance.
  • ||||||||||  Real-World Outcome of Metastatic ALK-Positive Non-Small Cell Lung Cancer Treated with Tyrosine Kinase Inhibitors (Exhibit Hall) -  Jul 25, 2023 - Abstract #IASLCWCLC2023IASLC_WCLC_2308;    
    Patients with advanced ALK-positive NSCLC have prolonged survival after the introduction of ALK TKIs with a median OS that exceeds 5 years when ALK TKIs are used in the first-line setting. Re-biopsies during treatment are needed to enhance our understanding of resistance mechanisms and the tumor dynamics that develop during ALK TKI therapy and to increase individualized management of this disease within precision medicine.
  • ||||||||||  Review, Journal:  Importance of ROS1 gene fusions in non-small cell lung cancer. (Pubmed Central) -  Jul 17, 2023   
    There are currently numerous FDA-approved agents for these tumors, including crizotinib and entrectinib; however, there is in-vitro sensitivity data and clinical data documenting responses to ceritinib and lorlatinib...To combat the mechanisms of resistance, novel agents such as repotrectenib, cabozantinib, talotrectinib, and others are being developed. In this article, we examine the literature pertaining to patients with ROS1 tumors, including epidemiology, clinical outcomes, resistance mechanisms, and treatment options.